Search results

  1. ME/CFS Skeptic

    How did Fibromyalgia become a brain disease? Disentangling conjecture and truth.

    I meant chronic unexplained widespread pain which I think is what the fibromyalgia diagnosis is mostly used for (this may differ pre region though). Seems to occur in a similar population to ME/CFS (mostly adult females), and shows some overlap in symptoms but the energy limitations, PEM, POTS...
  2. ME/CFS Skeptic

    How did Fibromyalgia become a brain disease? Disentangling conjecture and truth.

    8% seems far too high but my impression is that it is at least double that of ME/CFS.
  3. ME/CFS Skeptic

    How did Fibromyalgia become a brain disease? Disentangling conjecture and truth.

    I once wrote this: https://www.s4me.info/threads/central-sensitization-a-matter-of-concern.5346/
  4. ME/CFS Skeptic

    Agomelatine but not melatonin improves fatigue perception: A longitudinal proof-of-concept study, Pardini et al, 2014

    Thanks for the tag. I wasn't aware of this Italian study. Had a quick look and it seems interesting that the response between melatonin and agomelatonine was so different.
  5. ME/CFS Skeptic

    Phase 2b program with sonlicromanol in patients with mitochondrial disease due to m.3243A>G mutation, 2025, Smeitink et al.

    The reason for posting this is that the Dutch government research funder ZonMw has funded a stud on this drug (sonlicromanol) for Long Covid patients. It's led by Michele van Vugt at Amsterdam University...
  6. ME/CFS Skeptic

    Phase 2b program with sonlicromanol in patients with mitochondrial disease due to m.3243A>G mutation, 2025, Smeitink et al.

    Abstract Mitochondrial disease incorporates a group of rare conditions with no approved treatment to date, except for Leber hereditary optic neuropathy. Therapeutic options to alleviate the symptoms of mitochondrial disease are urgently needed. Sonlicromanol is a promising candidate, as it...
  7. ME/CFS Skeptic

    Trial Report Low Dose Rapamycin Alleviates Clinical Symptoms of Fatigue and PEM in ME/CFS Patients via Improvement of Autophagy, 2025, Ruan et al

    Agree with others that this study design isn't able to show what the real effect is, but it does give a ceiling to how large the effect might be. I'm assuming that the 40 patients who kept paying for the drug had a better response than the sample as a whole (the paper says that a common reason...
  8. ME/CFS Skeptic

    Neurodevelopment Genes Encoding Olduvai Domains Link Myalgic Encephalomyelitis to Neuropsychiatric Disorders, 2025, Lidbury et al

    The Nevada study which they used as a validation cohort was originally published in 2016 and discussed here (it highlighted GRIK3 which plays a role in neurotransmission). Genome-wide association analysis identifies genetic variations in subjects with [ME/CFS], 2016, Schlauch et al | Science for ME
  9. ME/CFS Skeptic

    EU: News from the European ME Coalition (EMEC)

    1) Important news: there is now a much greater chance than ever before for #MECFS scientists to obtain funding from #HorizonEurope. 2) For the #HorizonEurope call Tackling high-burden for patients and under-researched medical conditions (HORIZON-HLTH-2025-01-DISEASE-07) the Commission has...
  10. ME/CFS Skeptic

    Neurodevelopment Genes Encoding Olduvai Domains Link Myalgic Encephalomyelitis to Neuropsychiatric Disorders, 2025, Lidbury et al

    This paper comments on this: Reference 21 is: Pooling/bootstrap-based GWAS (pbGWAS) identifies new loci modifying the age of onset in PSEN1 p.Glu280Ala Alzheimer's disease - PubMed Abstract The literature on GWAS (genome-wide association studies) data suggests that very large sample sizes...
  11. ME/CFS Skeptic

    Submaximal 2-day cardiopulmonary exercise testing to assess exercise capacity and [PESE] in people with long COVID 2025 Thomas et al

    Thanks. I suspect this inflates their effect size. Not sure why they didn't simply use cohen's d as the data is quite similar to a normal distribution.
  12. ME/CFS Skeptic

    Submaximal 2-day cardiopulmonary exercise testing to assess exercise capacity and [PESE] in people with long COVID 2025 Thomas et al

    Also note that this study used a submaximal test in contras to previous CPET-studies which I think all used a maximal test.
  13. ME/CFS Skeptic

    Submaximal 2-day cardiopulmonary exercise testing to assess exercise capacity and [PESE] in people with long COVID 2025 Thomas et al

    In table 4 of the paper, they report an effect size for Work rate at the first ventilatory threshold of 0.742. I don't see how it can be that large. I got an estimate of cohen d = 0.44 when using the sd of the difference between CPETs and d = 0.34 when using the poolsed sd of CPET1.
  14. ME/CFS Skeptic

    Submaximal 2-day cardiopulmonary exercise testing to assess exercise capacity and [PESE] in people with long COVID 2025 Thomas et al

    Thanks for the suggestion. The best I got was 57 matches out of 68 using height, age and weight (sex has a lot of NA's in dataset 1 for some reason). Some might be errors in data insertion. For example there's only 1 participant with height 175 cm and weight 74 kg in both datasets but in...
  15. ME/CFS Skeptic

    Submaximal 2-day cardiopulmonary exercise testing to assess exercise capacity and [PESE] in people with long COVID 2025 Thomas et al

    Tried to make some plots with dotted lines showing the trajectory of participants: I don't think that the participants who had a workload of 0 were excluded (there was one at CPET1 and 5 at CPET2).
  16. ME/CFS Skeptic

    Submaximal 2-day cardiopulmonary exercise testing to assess exercise capacity and [PESE] in people with long COVID 2025 Thomas et al

    The raw data that they posted includes two datasets (separate sheets in Excel) but I don't see how these can be linked. Both have 68 rows, so I assumed this were from the same participants and we could just bind the columns. But the sex columns from both sheets do not match suggesting that...
  17. ME/CFS Skeptic

    Submaximal 2-day cardiopulmonary exercise testing to assess exercise capacity and [PESE] in people with long COVID 2025 Thomas et al

    Another issue is the a higher number of missing values. Was looking at VO2 at VT1. 29 out of 68 (43%) of participants had missing data at either CPET1 or CPET 2.
  18. ME/CFS Skeptic

    Unwilling or unable? Interpreting effort task performance in myalgic encephalomyelitis/chronic fatigue syndrome, 2025, Kirvin-Quamme et al

    Thanks for the explanation! So it's possible that a critique in Matters Arising - Nature Comms, is still in the pipeline? Perhaps somebody could write to the editors at Nature Comms to ask about this? If it got rejected after peer review, it would be interested to know what the critique said...
  19. ME/CFS Skeptic

    Submaximal 2-day cardiopulmonary exercise testing to assess exercise capacity and [PESE] in people with long COVID 2025 Thomas et al

    Despite all the talk about PEM/PESE, it seems that they did not measure this symptom (in contrast to many other Long Covid symptoms)?
  20. ME/CFS Skeptic

    T and B cell responses against Epstein–Barr virus in primary sclerosing cholangitis, 2025, ElAbd et al

    Sounds interesting.
Back
Top Bottom